Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SAN

Sanofi (SAN)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:EU:SAN
DateTimeSourceHeadlineSymbolCompany
27/06/202407:30GlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
27/06/202407:30GlobeNewswire Inc.Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ansEU:SANSanofi
27/06/202407:30GlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
26/06/202403:32GlobeNewswire Inc.Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »EU:SANSanofi
26/06/202403:32GlobeNewswire Inc.Press Release: Availability of the Q2 2024 Aide-mémoireEU:SANSanofi
21/06/202417:30GlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
21/06/202417:30GlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
21/06/202417:30GlobeNewswire Inc.Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de SanofiEU:SANSanofi
21/06/202415:00GlobeNewswire Inc.Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilieEU:SANSanofi
21/06/202415:00GlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
21/06/202415:00GlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
20/06/202422:00GlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
20/06/202422:00GlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
20/06/202422:00GlobeNewswire Inc.Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en AfriqueEU:SANSanofi
13/06/202404:19GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – May 2024EU:SANSanofi
13/06/202404:19GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024EU:SANSanofi
04/06/202406:15GlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
04/06/202406:15GlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
04/06/202406:15GlobeNewswire Inc.Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]EU:SANSanofi
31/05/202420:00GlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
31/05/202420:00GlobeNewswire Inc.Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salariéEU:SANSanofi
31/05/202420:00GlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
31/05/202415:00GlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
31/05/202415:00GlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
31/05/202415:00GlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
30/05/202423:01GlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Your Recent History

Delayed Upgrade Clock